Patent search ap:("ABBVIE INC.") AND inv:"Noel S. Wilson" Page 1

1.

发明申请
PRIMARY CARBOXAMIDES AS BTK INHIBITORS 有权

公开(公告)号：US20210179556A1

公开(公告)日：2021-06-17

申请号：US17173613

申请日：2021-02-11

Applicant: AbbVie Inc.

Inventor： Dominique Bonafoux , Heather Michele Davis , Kristine E. Frank , Michael M. Friedman , J. Martin Herold , Michael Z. Hoemann , Raymond Huntley , Augustine Osuma , George Sheppard , Gagandeep Kaur Somal , Jennifer Van Camp , Stacy Anne Van Epps , Anil Vasudevan , Grier Allan Wallace , Lu Wang , Lu Wang , Zhi Wang , Noel S. Wilson , Xiangdong Xu

IPC: C07D209/08 , C07D487/04 , C07D417/12 , C07D471/04 , C07D417/14 , C07D401/14 , C07D403/14 , C07D231/56 , C07D401/12 , A61P35/00 , C07D513/04 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/18 , C07D401/04 , C07D403/04 , C07D403/10 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

2.

发明授权
Indazolones as modulators of TNF signaling 有权

公开(公告)号：US10273238B2

公开(公告)日：2019-04-30

申请号：US15852179

申请日：2017-12-22

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger , Andrew Burchat , Justin Dietrich , Michael Friedman , David Ihle , David Kinsman , Kelly Mullen , Augustine Osuma , Anil Vasudevan , Noel S. Wilson

IPC: C07D487/04 , C07D519/00 , C07D498/04

Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

3.

发明申请
MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF 审中-公开

公开(公告)号：US20180346484A1

公开(公告)日：2018-12-06

申请号：US15882008

申请日：2018-01-29

Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.

Inventor： Irini Akritopoulou-Zanze , Wilfried Braje , Stevan W. Djuric , Noel S. Wilson , Sean C. Turner , Albert W. Kruger , Ana-Lucia Relo , Shashank Shekhar , Dennie S. Welch , Hongyu Zhao , Jorge Gandarilla , Alan F. Gasiecki , Huanqiu Li , Christina M. Thompson , Min Zhang

IPC: C07D513/04 , C07D495/16 , C07D487/04 , C07D495/04 , C07D491/04 , C07D491/044

CPC classification number: C07D513/04 , C07D487/04 , C07D491/04 , C07D491/044 , C07D495/04 , C07D495/16

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

4.

发明授权
Heterocyclic kinase inhibitors 有权

公开(公告)号：US10280184B2

公开(公告)日：2019-05-07

申请号：US15304131

申请日：2015-04-16

Applicant: AbbVie Inc.

Inventor： Michael M. Friedman , Philip Cox , Kristine E. Frank , Michael Z. Hoemann , Augustine Osuma , Noel S. Wilson , Xiangdong Xu , Kevin Cusack , Raymond Huntley , J. Martin Herold

IPC: C07D471/04 , C07D519/00 , A61K31/437 , C07D487/04 , C07D498/04

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

5.

发明授权
Indazolones as modulators of tnf signaling 有权

公开(公告)号：US10160748B2

公开(公告)日：2018-12-25

申请号：US15670708

申请日：2017-08-07

Applicant: AbbVie Inc.

Inventor： Maria Argiriadi , Eric Breinlinger , Justin D. Dietrich , Michael Friedman , David Ihle , Michael Morytko , Kelly Mullen , Augustine Osuma , Gloria Y. LoSchiavo , Noel S. Wilson

IPC: C07D403/04 , C07F9/6558 , C07D413/04 , C07D471/04 , C07D405/04 , C07D491/107 , C07D487/04 , C07D401/14 , C07D417/04 , C07D403/14 , C07D498/04 , C07D401/04 , C07D413/14 , C07D405/14 , C07D417/14

Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

6.

发明授权
Primary carboxamides as BTK inhibitors 有权
Title translation: 主要羧酰胺作为BTK抑制剂

公开(公告)号：US09567339B2

公开(公告)日：2017-02-14

申请号：US14315504

申请日：2014-06-26

Applicant: AbbVie Inc.

Inventor： Dominique Bonafoux , Heather M. Davis , Kristine E. Frank , Michael M. Friedman , J. Martin Herold , Michael Z. Hoemann , Raymond Huntley , Augustine Osuma , George Sheppard , Gagandeep K. Somal , Jennifer Van Camp , Stacy A. Van Epps , Anil Vasudevan , Grier A. Wallace , Lu Wang , Lu Wang , Zhi Wang , Noel S. Wilson , Xiangdong Xu

IPC: C07D487/04 , C07D417/12 , C07D471/04 , C07D209/08 , C07D417/14 , C07D401/14 , C07D403/14 , C07D231/56 , C07D401/12

CPC classification number: C07D209/08 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/18 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Abstract translation: 本发明提供式（I）化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学病症。

7.

发明申请
INDAZOLONES AS MODULATORS OF TNF SIGNALING 审中-公开
Title translation: 作为TNF信号调节剂的吲哚酮

公开(公告)号：US20160304496A1

公开(公告)日：2016-10-20

申请号：US15130279

申请日：2016-04-15

Applicant: AbbVie Inc.

Inventor： Maria Argiriadi , Eric Breinlinger , Justin D. Dietrich , Michael Friedman , David Ihle , Michael Morytko , Kelly Mullen , Augustine Osuma , Glora Y. Lo Schiavo , Noel S. Wilson

IPC: C07D403/04 , C07D403/14 , C07D491/107 , C07D405/14 , C07D487/04 , C07D405/04 , C07D417/14 , C07D401/04 , C07D417/04 , C07D413/04 , C07D471/04 , C07F9/6558 , C07D401/14 , C07D498/04

CPC classification number: C07D403/04 , C07D401/04 , C07D401/14 , C07D403/14 , C07D405/04 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/107 , C07D498/04 , C07F9/65583

Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

Abstract translation: 本公开提供吲哚酮化合物，药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本公开的化合物可用于治疗免疫学和肿瘤学病症。

8.

发明申请
BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS 有权

公开(公告)号：US20220213092A1

公开(公告)日：2022-07-07

申请号：US17552396

申请日：2021-12-16

Applicant: AbbVie Inc.

Inventor： David A. DeGoey , Felix DeAnda, Jr. , Amanda W. Dombrowski , Igor Dubovyk , Stephen N. Greszler , Dimitri Khrakovsky , Chih-Hung Lee , James N. Newton , Elizabeth L. Noey , Akinori Okano , Kevin B. Sippy , Andrew J. Souers , Longcheng Wang , Noel S. Wilson , Jeffery A. Zablocki

IPC: C07D471/04 , C07D519/00 , C07D487/04

Abstract: The present invention provides for compounds of formula (I) wherein A, R1, R2, R4, W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.